Loading...
•
Mar 31, 2021
Alkermes Q1 2021 Earnings Report
Alkermes reported solid performance of VIVITROL and ARISTADA, achieving GAAP loss per share of $0.14 and non-GAAP earnings per share of $0.11, supported by disciplined expense management, and reiterated financial expectations for 2021.
Key Takeaways
Alkermes reported first quarter revenues of $251.4 million, reflecting solid performance of VIVITROL and ARISTADA. The company achieved a GAAP loss per share of $0.14 and non-GAAP earnings per share of $0.11. They reiterated their financial expectations for 2021.
Total revenues for the quarter were $251.4 million.
Net sales of VIVITROL were $74.5 million, representing a decrease of approximately 5% compared to the same period in the prior year.
Net sales of ARISTADA were $55.4 million, representing an increase of approximately 9% compared to the same period in the prior year.
Non-GAAP net income was $17.8 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.11.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Revenue
CapyFin.comARISTADA Revenue
CapyFin.com Forward Guidance
Alkermes reiterates its financial expectations for 2021, and the assumptions underlying such expectations, as set forth in its press release dated Feb. 11, 2021.